ArticleDiscover oncology2026
Mapping HLA class I and II allele associations with hepatitis C related liver disease progression in an Egyptian cohort.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND AND
aimHost genetic factors, particularly human leukocyte antigen (HLA) polymorphisms, play a crucial role in determining the immunological outcome of Hepatitis C virus (HCV) infection. These genetic variations may influence susceptibility, disease progression, and the development of severe liver complications such as liver cirrhosis and hepatocellular carcinoma (HCC). Given the predominance of HCV genotype 4 in Egypt, this study was designed to investigate the association between specific HLA Class I and Class II alleles and clinical outcomes in an Egyptian cohort of patients with chronic HCV infection. PATIENTS AND
methodsA total of 223 participants were enrolled and stratified into four clinically defined categories: healthy controls (n = 55), patients with chronic hepatitis C (n = 86), liver cirrhotic patients (n = 42), and individuals with HCV-related HCC (n = 40). HLA genotyping was performed using the LABType
resultsThis study identified differential HLA allele frequencies across HCV-related liver disease outcomes in an Egyptian cohort. HLA-DQB1*03, HLA-B*27, HLA-C*05, and HLA-A*26 showed high frequencies in healthy controls, whereas HLA-DRB1*14, HLA-A*69, HLA-B*52, HLA-B*58, and HLA-DRB1*15 appeared enriched in disease groups. Only HLA-DQB1*03 remained significant after Bonferroni correction. However, given the small sample size and lack of comprehensive national HLA data for direct comparison, these observations should be interpreted with caution. Alleles, such as HLA-B*44 and HLA-C*05, appeared absent in the HCC subgroup, though the significance of this finding remains uncertain due to low background frequencies in the control group.
conclusionThese preliminary data suggest possible associations of certain HLA alleles and HCV-related liver disease progression in Egyptian patients, possibly serving as candidate biomarkers for risk stratification. Nonetheless, larger, population-based studies with confirmed HCV genotyping, comprehensive treatment data, and updated controls reflecting current Egyptian HLA allele frequencies are needed to substantiate these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.